相关实验视频
Updated: Jul 8, 2025

07:34
Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies
Published on: April 11, 2012
19.5K
乙化物通过向SOD2来预防败血症诱导的心肌损伤
Xin Li1,2, Zuojing Zhang1, Xiaoxuan Zhang1,3
1Department of Anesthesiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Journal of medicinal food
|December 15, 2023
概括
乙化 (ECH) 通过增加SOD2表达来有效治疗败血症引起的心肌损伤,从而减少有害的活性氧物种 (ROS). 这种机制保护心脏功能,并减少败血症小鼠的纤维化.
科学领域:
- 心血管生物学 心血管生物学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 败血症经常导致心肌损伤,导致显著的死亡率.
- 乙化 (ECH) 是一种天然化合物,在缓解心肌损伤方面具有潜力.
- ECH在败血症中的心脏保护作用的确切机制尚不清楚.
研究的目的:
- 调查 Echinacoside (ECH) 对败血症引起的心肌损伤的保护作用.
- 阐明ECH治疗作用的基础分子机制.
- 确定参与ECH有益作用的关键分子标.
主要方法:
- 一个结刺 (CLP) 鼠标模型被用于诱导败血症.
- 心声图和马森染色评估了心脏功能和纤维化.
- 转录组分析和网络药理学确定了重叠的目标.
- 聚合酶链反应 (PCR) 和ROS试验评估了基因表达和氧化应激.
- SOD2 抑制剂实验证实了鉴定目标的作用.
主要成果:
- 在CLP小鼠中,ECH治疗改善了心脏功能,并减少了心脏纤维化.
- 分析显示,败血症诱导的心肌损伤和ECH之间有51个重叠的目标,其中反应性氧物种 (ROS) 途径是突出的.
- ECH的使用显著增加了SOD2表达,并降低了ROS水平.
- 抑制SOD2消除了ECH对死亡率,心脏功能和纤维化的保护作用,同时增加了ROS.
结论:
- 乙化 (ECH) 对败血症引起的心肌损伤具有显著的保护作用.
- 治疗机制涉及对氧化脱酶2 (SOD2) 表达的上调调节.
- 这种上调导致活性氧物种 (ROS) 生产减少,从而减轻心脏损伤.
更多相关视频
相关概念视频
Heart Failure Drugs: Inotropic Agents
594
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436

